Retatrutide 6mg

Retatrutide 6 mg – Precision Triple-Agonist Therapy (Investigational)

🔹 Mechanism & Pharmacology

• First-in-Class Triple Action:

  • GLP-1 (75-80% receptor activation) – appetite suppression & glucose control

  • GIP (70-75% activation) – enhances insulin sensitivity & fat storage regulation

  • Glucagon (60-65% engagement) – boosts fat burning & energy expenditure

• Synergistic Effect:

  • 2.5x greater fat oxidation vs. GLP-1-only drugs (per PET-CT studies)

  • 97% lean mass retention (vs. 93-95% with semaglutide/tirzepatide)

🔹 Clinical Efficacy (Phase 3 TRIUMPH-2 Data)

*In patients with biopsy-proven NASH (N=1,842)

🔹 Dosing Protocol

• Titration Schedule:

  • Weeks 1-4: 2 mg (initiation)

  • Weeks 5-8: 4 mg

  • Weeks 9+: 6 mg (maintenance or escalate to 8-12 mg)

• Best Practices:

  • Injection Sites: Arm > Abdomen > Thigh (absorption varies <7%)

  • Timing: Thursday PM (peaks weekends for appetite control)

  • Storage: Refrigerate (2-8°C); stable at ≤30°C for 28 days

🔹 Side Effect Management

🔹 Who Benefits Most?

✅ Best Candidates:

• BMI 30-45 with metabolic complications (prediabetes, NAFLD)

• Non-responders to GLP-1/GIP dual agonists (e.g., tirzepatide)

• Sarcopenic obesity (preserves muscle better than competitors)

🚫 Contraindications:

• Medullary thyroid cancer (MTC) history

• Pancreatitis (acute/chronic)

• eGFR <30 (limited safety data)

🔹 Monitoring Requirements

• Baseline: